All In Biotech

Drug Trial Radar · NCT06901505

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

Jul 24, 2025

Primary completion

Aug 12, 2026

Study completion Aug 12, 2026

Sponsor

Lead sponsor
Akebia TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimulating agent for the treatment of anemia in in-center hemodialysis participants with end-stage kidney disease (ESKD). A subset of sites will participate in a red blood cell (RBC) sub-study where changes in the phenotype of RBCs in response to vadadustat treatment relative to methoxy polyethylene glycol-epoetin beta treatment in DD-CKD participants with anemia will be assessed. A separate informed consent form (ICF) will be signed by these participants who opt to be in the RBC sub-study. Of the 350 participants in the main study, approximately 28 participants will also be enrolled into the RBC sub-study. The total duration of the study is approximately 35 Weeks including screening and follow-up.

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

  • Erythropoiesis-Stimulating Agent (ESA)Drug

    Administered by intra-venous (IV) infusion.

  • VadadustatDrug

    300mg, oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in hemoglobin (Hb)Time frame: Baseline and the mean of Week 20 to 24

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • DaVita Research Site

    Montgomery, Alabama

  • DaVita Research Site

    Hartford, Connecticut

  • DaVita Research Site

    Middlebury, Connecticut

  • DaVita Research Site

    Columbus, Georgia

  • DaVita Research Site #1

    Minneapolis, Minnesota

  • DaVita Research Site

    Minneapolis, Minnesota

  • DaVita Research Site

    Henderson, Nevada

  • DaVita Research Site

    Las Vegas, Nevada

  • DaVita Research Site #1

    El Paso, Texas

  • DaVita Research Site

    El Paso, Texas

  • DaVita Research Site #1

    Houston, Texas

  • DaVita Research Site

    Houston, Texas

  • DaVita Research Site #1

    San Antonio, Texas

  • DaVita Research Site #2

    San Antonio, Texas

  • DaVita Research Site

    San Antonio, Texas

  • DaVita Research Site

    The Woodlands, Texas

  • DaVita Research Site #1

    Norfolk, Virginia

  • DaVita Research Site

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.